Cite
Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency.
MLA
Valayannopoulos, Vassili, et al. “Sebelipase Alfa over 52 Weeks Reduces Serum Transaminases, Liver Volume and Improves Serum Lipids in Patients with Lysosomal Acid Lipase Deficiency.” Journal of Hepatology, vol. 61, no. 5, Nov. 2014, pp. 1135–42. EBSCOhost, https://doi.org/10.1016/j.jhep.2014.06.022.
APA
Valayannopoulos, V., Malinova, V., Honzík, T., Balwani, M., Breen, C., Deegan, P. B., Enns, G. M., Jones, S. A., Kane, J. P., Stock, E. O., Tripuraneni, R., Eckert, S., Schneider, E., Hamilton, G., Middleton, M. S., Sirlin, C., Kessler, B., Bourdon, C., Boyadjiev, S. A., … Quinn, A. G. (2014). Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. Journal of Hepatology, 61(5), 1135–1142. https://doi.org/10.1016/j.jhep.2014.06.022
Chicago
Valayannopoulos, Vassili, Vera Malinova, Tomas Honzík, Manisha Balwani, Catherine Breen, Patrick B Deegan, Gregory M Enns, et al. 2014. “Sebelipase Alfa over 52 Weeks Reduces Serum Transaminases, Liver Volume and Improves Serum Lipids in Patients with Lysosomal Acid Lipase Deficiency.” Journal of Hepatology 61 (5): 1135–42. doi:10.1016/j.jhep.2014.06.022.